# Paclitaxel, Bevacizumab And Adjuvant Intraperitoneal Carboplatin in Treating Patients Who Had Initial Debulking Surgery for Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

> **NCT00079430** · PHASE1 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 113 (actual)

## Conditions studied

- Brenner Tumor
- Fallopian Tube Cancer
- Ovarian Clear Cell Cystadenocarcinoma
- Ovarian Endometrioid Adenocarcinoma
- Ovarian Mixed Epithelial Carcinoma
- Ovarian Mucinous Cystadenocarcinoma
- Ovarian Serous Cystadenocarcinoma
- Ovarian Undifferentiated Adenocarcinoma
- Primary Peritoneal Cavity Cancer
- Stage II Ovarian Epithelial Cancer
- Stage III Ovarian Epithelial Cancer
- Stage IV Ovarian Epithelial Cancer

## Interventions

- **PROCEDURE:** adjuvant therapy
- **DRUG:** paclitaxel
- **DRUG:** carboplatin
- **BIOLOGICAL:** bevacizumab

## Key facts

- **NCT ID:** NCT00079430
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-06
- **Primary completion:** 2011-05
- **Final completion:** —
- **Target enrollment:** 113 (ACTUAL)
- **Last updated:** 2019-07-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00079430

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00079430, "Paclitaxel, Bevacizumab And Adjuvant Intraperitoneal Carboplatin in Treating Patients Who Had Initial Debulking Surgery for Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00079430. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*